Bowman & Co S.C. Purchases 993 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bowman & Co S.C. grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,927 shares of the medical research company’s stock after purchasing an additional 993 shares during the quarter. Bowman & Co S.C.’s holdings in Edwards Lifesciences were worth $1,009,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of EW. International Assets Investment Management LLC boosted its holdings in Edwards Lifesciences by 9,720.7% during the 4th quarter. International Assets Investment Management LLC now owns 106,064 shares of the medical research company’s stock valued at $8,087,000 after acquiring an additional 104,984 shares during the period. Lindbrook Capital LLC boosted its holdings in Edwards Lifesciences by 6.8% during the 4th quarter. Lindbrook Capital LLC now owns 3,830 shares of the medical research company’s stock valued at $292,000 after acquiring an additional 245 shares during the period. Commerzbank Aktiengesellschaft FI purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $218,000. RWA Wealth Partners LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $238,000. Finally, Parkside Financial Bank & Trust lifted its holdings in Edwards Lifesciences by 17.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,125 shares of the medical research company’s stock worth $86,000 after buying an additional 164 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of several research analyst reports. Evercore ISI dropped their price objective on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a report on Thursday, July 25th. Wells Fargo & Company dropped their price objective on Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating for the company in a report on Thursday, July 25th. Truist Financial cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $110.00 to $82.00 in a report on Thursday, July 25th. Robert W. Baird cut Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $102.00 to $70.00 in a report on Thursday, July 25th. Finally, Barclays lowered their target price on Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Fourteen investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $82.10.

Edwards Lifesciences Stock Down 0.6 %

Shares of Edwards Lifesciences stock traded down $0.45 on Friday, reaching $70.85. The company’s stock had a trading volume of 3,706,630 shares, compared to its average volume of 4,083,428. The company has a market capitalization of $42.69 billion, a price-to-earnings ratio of 30.54, a P/E/G ratio of 2.57 and a beta of 1.11. The firm’s fifty day simple moving average is $79.04 and its two-hundred day simple moving average is $85.39. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.66 EPS. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,867 shares of company stock valued at $2,077,526. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.